Vestal Point Capital’s Structure Therapeutics GPCR Stock Holding History

Vestal Point Capital’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,000	Closed	-$2.43M	–	101
2025 Q4	$2.43M	Buy	+35,000	New	+$1.43M	0.08%	68
2025 Q3	–	Sell	-1,200,000	Closed	-$24.9M	–	87
2025 Q2	$24.9M	Sell	1,200,000 -588,990	-33%	-$13M	1.31%	28
2025 Q1	$31M	Buy	1,788,990 +63,990	+4%	+$1.57M	2.21%	15
2024 Q4	$46.8M	Buy	1,725,000 +575,000	+50%	+$20.4M	2.77%	11
2024 Q3	$50.5M	Buy	1,150,000 +590,000	+105%	+$22.8M	3.83%	6
2024 Q2	$22M	Buy	+560,000	New	+$23M	1.64%	19

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vestal Point Capital's GPCR Position: Q1 2026 in Review

Vestal Point Capital sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 35,000 shares — an estimated $2.43M sold.

Vestal Point Capital first reported a position in GPCR in Q2 2024 and held it in 6 quarters. The position peaked at $50.5M in Q3 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Vestal Point Capital reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
Vestal Point Capital sold 35,000 Structure Therapeutics shares in Q1 2026, an estimated $2.43M.
Vestal Point Capital first reported a position in Structure Therapeutics in Q2 2024 and held it in 6 quarters.
Vestal Point Capital's Structure Therapeutics position peaked at $50.5M in Q3 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.